23199-54-4

Upstream product

• 20705-05-9 1,1,2-trifluoro-1-iodoethane 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 14439-71-5 2'-benzoyl-2-bromo-acetanilide 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 2898-08-0 2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one 

Downstream Products

• 177954-77-7 3-Azido-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepine 
• 820215-28-9 3-hydroxy-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,4-benzodiazepine 
• 177954-79-9 (R)-2-Amino-N-[(R)-2-oxo-5-phenyl-1-(2,2,2-trifluoro-ethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-phenyl-propionamide 
• 177954-81-3 3R-3-Amino-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4]diazepine 
• 177954-78-8 3-amino-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-benzo<1,4>diazepine 
• 220892-17-1 3-oximino-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-benzo<1,4>diazepine 

Relevant academic research and scientific papers

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to substituted benozdiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

METHOD FOR TREATING MENIERE'S DISEASE

A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.

2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines

This invention is concerned with novel compounds represented by structural formula I STR1 where X and Y are independently hydrogen, chloro, fluoro, bromo, iodo, or trifluoromethyl and n is 0, 1 or 2; R is hydrogen, fluoro, chloro, bromo, iodo, or trifluor